1 week Ago By Defense World Staff
Monopar Therapeutics Inc. ( NASDAQ:MNPR – Free Report ) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for Monopar Therapeutics in a research note issued on Wednesday, January 22nd. HC Wainwright analyst S.
Lee now anticipates that the company will earn $0.70 per share for the year, up from their previous forecast of $0.12.
HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.
65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.
04 EPS. Other research analysts also recently issued reports about the stock. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th.
They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler assumed coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th.
They issued an “overweight” rating and a $72.00 price target on the stock. Monopar Therapeutics Stock Performance Shares of MNPR opened at $41.
46 on Friday. The firm has a market cap of $252.91 million, a price-to-earnings ratio of -21.
05 and a beta of 1.23. Monopar Therapeutics has a fifty-two week low of $1.
54 and a fifty-two week high of $41.94. The firm has a 50 day moving average price of $24.
65 and a 200-day moving average price of $12.60. Monopar Therapeutics ( NASDAQ:MNPR – Get Free Report ) last released its quarterly earnings data on Friday, November 8th.
The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.
09. Insider Buying and Selling In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The shares were purchased at an average price of $16.
25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.
50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website .
34.90% of the stock is currently owned by insiders. Monopar Therapeutics Company Profile ( Get Free Report ) Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. Read More Five stocks we like better than Monopar Therapeutics Find and Profitably Trade Stocks at 52-Week Lows Bloom Energy: Powering the Future With Decentralized Energy 3 Stocks to Consider Buying in October Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul Why Understanding Call Option Volume is Essential to Successful Options Trading Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
